Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol

Robert U Newton, Stacey A Kenfield, Nicolas H Hart, June M Chan, Kerry S Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A Galvão, Charles J Ryan, Fred Saad, Robert U Newton, Stacey A Kenfield, Nicolas H Hart, June M Chan, Kerry S Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A Galvão, Charles J Ryan, Fred Saad

Abstract

Introduction: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Methods and analysis: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatment-naïve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation.

Ethics and dissemination: Validation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation.

Trial registration number: NCT02730338.

Keywords: disease progression; immune function; inflammation; physical activity; tumour biology.

Conflict of interest statement

Competing interests: MB and SG are employees of Movember Foundation, which is the funder of this research.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Schematic overview of the INTERVAL-GAP4 trial. 1RM, one-repetition maximum; ACSM, American College of Sports Medicine; CPET, cardiopulmonary exercise test; ECG, echocardiogram; INTERVAL-GAP4, Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer, Global Action Plan 4.

References

    1. Newton RU, Galvão DA. Accumulating evidence for physical activity and prostate cancer survival: time for a definitive trial of exercise medicine? Eur Urol 2016;70:586–7. 10.1016/j.eururo.2016.04.018
    1. Galvão DA, Nosaka K, Taaffe DR, et al. . Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006;38:2045–52. 10.1249/01.mss.0000233803.48691.8b
    1. Galvão DA, Taaffe DR, Spry N, et al. . Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010;28:340–7. 10.1200/JCO.2009.23.2488
    1. Kenfield SA, Stampfer MJ, Giovannucci E, et al. . Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011;29:726–32. 10.1200/JCO.2010.31.5226
    1. Friedenreich CM, Wang Q, Neilson HK, et al. . Physical activity and survival after prostate cancer. Eur Urol 2016;70:576–85. 10.1016/j.eururo.2015.12.032
    1. Hardee JP, Porter RR, Sui X, et al. . The effect of resistance exercise on all-cause mortality in cancer survivors. Mayo Clin Proc 2014;89:1108–15. 10.1016/j.mayocp.2014.03.018
    1. Taaffe DR, Newton RU, Spry N, et al. . Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol 2017;72:293–9. 10.1016/j.eururo.2017.02.019
    1. Ryan CJ, Smith MR, Fizazi K, et al. . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60. 10.1016/S1470-2045(14)71205-7
    1. Beer TM, Armstrong AJ, Rathkopf DE, et al. . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33. 10.1056/NEJMoa1405095
    1. Galvão DA, Taaffe DR, Spry N, et al. . Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc 2018;50:393–9. 10.1249/MSS.0000000000001454
    1. Hart NH, Galvão DA, Newton RU. Exercise medicine for advanced prostate cancer. Curr Opin Support Palliat Care 2017;11:247–57. 10.1097/SPC.0000000000000276
    1. Hart NH, Newton RU, Spry NA, et al. . Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open 2017;7:e014458 10.1136/bmjopen-2016-014458
    1. Hawkins VN, Foster-Schubert K, Chubak J, et al. . Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. Med Sci Sports Exerc 2008;40:223–33. 10.1249/mss.0b013e31815bbba9
    1. Matsumoto AM, Bremner WJ. Serum testosterone assays--accuracy matters. J Clin Endocrinol Metab 2004;89:520–4. 10.1210/jc.2003-032175
    1. Stark JR, Li H, Kraft P, et al. . Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124:2683–9. 10.1002/ijc.24241
    1. Nicklas BJ, Hsu FC, Brinkley TJ, et al. . Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc 2008;56:2045–52. 10.1111/j.1532-5415.2008.01994.x
    1. Zimmer P, Jäger E, Bloch W, et al. . Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study. BMC Cancer 2013;13:272 10.1186/1471-2407-13-272
    1. Platz EA, Till C, Goodman PJ, et al. . Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009;18:2807–13. 10.1158/1055-9965.EPI-09-0472
    1. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008;123:1693–8. 10.1002/ijc.23715
    1. Halabi S, Lin CY, Kelly WK, et al. . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:671–7. 10.1200/JCO.2013.52.3696
    1. Scher HI, Morris MJ, Stadler WM, et al. . Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34:1402–18. 10.1200/JCO.2015.64.2702
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. 10.1016/j.ejca.2008.10.026
    1. Galvão DA, Taaffe DR, Cormie P, et al. . Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer 2011;11:517 10.1186/1471-2407-11-517
    1. Jones LW, Eves ND, Haykowsky M, et al. . Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol 2008;9:757–65. 10.1016/S1470-2045(08)70195-5
    1. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc 1987;82:171–85. 10.1080/01621459.1987.10478410
    1. Kraemer WJ, Ratamess N, Fry AC, et al. . Influence of resistance training volume and periodization on physiological and performance adaptations in collegiate women tennis players. Am J Sports Med 2000;28:626–33. 10.1177/03635465000280050201
    1. Martorelli S, Cadore EL, Izquierdo M, et al. . Strength training with repetitions to failure does not provide additional strength and muscle hypertrophy gains in young women. Eur J Transl Myol 2017;27:6339 10.4081/ejtm.2017.6339
    1. Trinh L, Plotnikoff RC, Rhodes RE, et al. . Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. Int J Behav Nutr Phys Act 2012;9:96 10.1186/1479-5868-9-96
    1. Karvinen KH, Courneya KS, Campbell KL, et al. . Correlates of exercise motivation and behavior in a population-based sample of endometrial cancer survivors: an application of the Theory of Planned Behavior. Int J Behav Nutr Phys Act 2007;4:21 10.1186/1479-5868-4-21
    1. Basen-Engquist K, Carmack CL, Li Y, et al. . Social-cognitive theory predictors of exercise behavior in endometrial cancer survivors. Health Psychol 2013;32:1137–48. 10.1037/a0031712
    1. Schmitz KH, Courneya KS, Matthews C, et al. . American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409–26. 10.1249/MSS.0b013e3181e0c112
    1. Wolin KY, Schwartz AL, Matthews CE, et al. . Implementing the exercise guidelines for cancer survivors. J Support Oncol 2012;10:171–7. 10.1016/j.suponc.2012.02.001
    1. Galvão DA, Spry N, Denham J, et al. . A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65 10.1016/j.eururo.2013.09.041
    1. Morey MC, Snyder DC, Sloane R, et al. . Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA 2009;301:1883–91. 10.1001/jama.2009.643
    1. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials. Support Care Cancer 2012;20:221–33. 10.1007/s00520-011-1271-0
    1. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res 2011;2:109–12. 10.4103/2229-3485.83221
    1. Richman EL, Kenfield SA, Stampfer MJ, et al. . Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 2011;71:3889–95. 10.1158/0008-5472.CAN-10-3932
    1. Peisch SF, Van Blarigan EL, Chan JM, et al. . Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol 2017;35:867–74. 10.1007/s00345-016-1914-3
    1. Kenfield SA, Batista JL, Jahn JL, et al. . Development and application of a lifestyle score for prevention of lethal prostate cancer. J Natl Cancer Inst 2016;108:108 10.1093/jnci/djv329
    1. Bonn SE, Sjölander A, Lagerros YT, et al. . Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev 2015;24:57–64. 10.1158/1055-9965.EPI-14-0707
    1. Chan AW, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Slade SC, Dionne CE, Underwood M, et al. . Consensus on Exercise Reporting Template (CERT): explanation and elaboration statement. Br J Sports Med 2016;50:1428–37. 10.1136/bjsports-2016-096651

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir